Beneficial Effects of Enalapril on Chlorhexidine Digluconate-Induced Liver Peritoneal Fibrosis in Rats

10.4077/CJP.2011.AMM073

Chung-Jen Lee；Yi-Maun Subeq；Ru-Ping Lee；Chen-Yen Ke；Nien-Tsung Lin；Bang-Gee Hsu

chlorhexidine digluconate ； peritoneal fibrosis ； enalapril

The Chinese Journal of Physiology

54卷4期（2011 / 08 / 01）

225 - 234

英文

Peritoneal fibrosis (PF) is a recognized complication of long-term peritoneal dialysis (PD) and can lead to ultrafiltration failure. The present study was designed to investigate the protective effects of enalapril on chlorhexidine digluconate-induced liver PF by decreasing transforming growth factor-β1 (TGF-β1) production in rats. PF was induced in Sprague-Dawley rats by daily administration of 0.5 ml 0.1% chlorhexidine digluconate in normal saline via PD tube for one week. Rats received daily intravenous injections of low dose enalapril (1 mg/kg), or high dose enalapril (2.5 mg/kg), for one week. After 7 days, conventional 4.25% Dianeal (30 ml) was administered via a PD catheter with a dwell time of 4 h and assessment of peritoneal function. At the end of dialysis, the rats were sacrificed and liver peritoneum was harvested for microscopic examination and immunohistochemistry. There was no significant difference in mean arterial pressure and heart rate between groups. After 4 h of PD, the D4/P4(subscript urea) level was reduced, the D4/D0 glucose level, serum and the dialysate TGF-β1 level was increased, the liver peritoneum was markedly thicker, and the expression of TGF-β1, alpha-smooth muscle actin (α-SMA), fibronectin, collagen and vascular endothelial growth factor (VEGF) were elevated in the PF group compared with the vehicle group. High dose of enalapril decreased the serum and dialysate TGF-β1 levels, decreased the thickness of the liver peritoneum, and decreased the expression of TGF-β1, α-SMA, fibronectin, collagen and VEGF-positive cells in the liver peritoneum. Low dose of enalapril did not protect against chlorhexidine digluconate-induced PF in the rat. Enalapril protected against chlorhexidine digluconate-induced PF in rats by decreasing TGF-β1 production.

1. Aroeira, L. S.,Aguilera, A.,Sánchez-Tomero, J. A.,Bajo, M. A.,del Peso, G.,Jiménez-Heffernan, J. A.,Selgas, R.,López-Cabrera, M.(2007).Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions.J. Am. Soc. Nephrol.,18,2004- 2013.
2. Atlas, S. A.(2007).The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.J. Manag. Care Pharm.,13(8 Suppl B),9-20.
3. Augustine, T.,Brown, P. W.,Davies, S. D.,Summers, A. M.,Wilkie, M. E.(2009).Encapsulating peritoneal sclerosis: clinical significance and implications.Nephron Clin. Pract.,111,c149-c154.
4. Augustyniak, R. A.,Maliszewska-Scislo, M.,Chen, H.,Fallucca, J.,Rossi, N. F.(2007).Acute angiotensin-converting enzyme inhibition evokes bradykinin-induced sympathetic activation in diabetic rats.Am. J. Physiol. Regul. Integr. Comp. Physiol.,293,R2260-R2266.
5. Carvajal, G.,Rodríguez-Vita, J.,Rodrigues-Díez, R.,Sánchez- López, E.,Rupérez, M.,Cartier, C.,Esteban, V.,Ortiz, A.,Egido, J.,Mezzano, S. A.,Ruiz-Ortega, M.(2008).Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation.Kidney Int.,74,585-595.
6. Duman, S.,Günal, A. I.,Sen, S.,Asçi, G.,Ozkahya, M.,Terzioglu, E.,Akçiçek, F.,Atabay, G.(2001).Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution?.Perit. Dial. Int.,21,219-224.
7. Erman, A.,Veksler, S.,Gafter, U.,Boner, G.,Wittenberg, C.,van Dijk, D. J.(2004).Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor β1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.J. Renin Angiotensin Aldosterone Syst.,5,146-151.
8. Faull, R. J.(2005).Bad and good growth factors in the peritoneal cavity.Nephrology,10,234-239.
9. Fusshoeller, A.(2008).Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis.Pediatr. Nephrol.,23,19-25.
10. Ke, C. Y.,Lee, C. C.,Lee, C. J.,Subeq, Y. M.,Lee, R. P.,Hsu, B. G.(2010).Aliskiren ameliorates chlorhexide digluconate-induced liver peritoneal fibrosis in rats.Eur. J. Clin. Invest.,40,301-309.
11. Liu, Y.(2004).Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention.J. Am. Soc. Nephrol.,15,1-12.
12. Margetts, P. J.,Kolb, M.,Galt, T.,Hoff, C. M.,Shockley, T. R.,Gauldie, J.(2001).Gene transfer of transforming growth factor-β1 to the rat peritoneum: effects on membrane function.J. Am. Soc. Nephrol.,12,2029-2039.
13. Mizobuchi, M.,Morrissey, J.,Finch, J. L.,Martin, D. R.,Liapis, H.,Akizawa, T.,Slatopolsky, E.(2007).Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.J. Am. Soc. Nephrol.,18,1796-1806.
14. Nessim, S. J.,Perl, J.,Bargman, J. M.(2010).The renin-angiotensinaldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum?.Kidney Int.,78,23-28.
15. Noh, H.,Ha, H.,Yu, M. R.,Kim, Y. O.,Kim, J. H.,Lee, H. B.(2005).Angiotensin II mediates high glucose-induced TGF-β1 and fibronectin upregulation in HPMC through reactive oxygen species.Perit. Dial. Int.,25,38-47.
16. Peters, H.,Rückert, M.,Gaedeke, J.,Liefeldt, L.,Ketteler, M.,Sharma, A. M.,Neumayer, H. H.(2003).Angiotensin-converting enzyme inhibition but not β-adrenergic blockade limits transforming growth factor-β overexpression in acute normotensive anti-thy1 glomerulonephritis.J. Hypertens.,21,771-780.
17. Piepho, R. W.(2000).Overview of the angiotensin-converting-enzyme inhibitors.Am. J. Health Syst. Pharm.,57(Suppl 1),S3-S7.
18. Purohit, V.,Brenner, D. A.(2006).Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium.Hepatology,43,872-878.
19. Radek, K. A.,Kovacs, E. J.,DiPietro, L. A.(2007).Matrix proteolytic activity during wound healing: modulation by acute ethanol exposure.Alcohol. Clin. Exp. Res.,31,1045-1052.
20. Ro, Y.,Hamada, C.,Inaba, M.,Io, H.,Kaneko, K.,Tomino, Y.(2007).Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats.Nephrol. Dial. Transplant.,22,2838-2848.
21. Sauter, M.,Cohen, C. D.,Wörnle, M.,Mussack, T.,Ladurner, R.,Sitter, T.(2007).ACE inhibitor and AT1-receptor blocker attenuate the production of VEGF in mesothelial cells.Perit. Dial. Int.,27,167-172.
22. Schmidt, D. W.,Flessner, M. F.(2008).Pathogenesis and treatment of encapsulating peritoneal sclerosis: basic and translational research.Perit. Dial. Int.,28(Suppl 5),S10-S15.
23. Suga, H.,Teraoka, S.,Ota, K.,Komemushi, S.,Furutani, S.,Yamauchi, S.,Margolin, S.(1995).Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats.Exp. Toxicol. Pathol.,47,287-291.
24. Toblli, J. E.,Stella, I.,de Cavanagh, E.,Angerosa, M.,Inserra, F.,Ferder, L.(1999).Enalapril prevents tubulointerstitial lesions by hyperoxaluria.Hypertension,33,225-231.
25. Türkay, C.,Yönem, O.,Arici, S.,Koyuncu, A.,Kanbay, M.(2008).Effect of angiotensin-converting enzyme inhibition on experimental hepatic fibrogenesis.Dig. Dis. Sci.,53,789-793.
26. Witowski, J.,Jörres, A.(2005).Preventing peritoneal fibrosis-an ace up our sleeve?.Perit. Dial. Int.,25,25-29.
27. Yu, L.,Border, W. A.,Anderson, I.,McCourt, M.,Huang, Y.,Noble, N. A.(2004).Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effect.Kidney Int.,66,1774-1784.
28. Yung, S.,Chan, T. M.(2003).Preventing peritoneal fibrosis-insights from the laboratory.Perit. Dial. Int.,23(Suppl 2),S37-S41.

1. Wu, Ming-Shun,Pan, Wen-Harn,Owaga, Eddy,Cheng, Shu-Yu,Chang, Jung-Su,Bai, Chyi-Huey(2014).Relationship between Hemoglobin Levels and Risk for Suspected Non-Alcoholic Fatty Liver in Taiwanese Adults.中國生理學雜誌,57(5),286-294.